DPP-4 inhibitors [37], which elevate incretin hormone levels to maintain glucose homeostasis, have yielded mixed findings regarding their association with intestinal obstruction: a smaller study of 40,615 patients indicated a potential risk [15], while a larger cohort study of 190,321 patients across three countries found no increased risk [16]. The gene discussed is GCG; the disease is intestinal obstruction.